Holocene Advisors, LP 89bio, Inc. Transaction History

Holocene Advisors, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $324,704 - $549,960	-39,939 Reduced 1.14%	3,450,689 $40.2 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $8.36 Million - $20.1 Million	1,254,823 Added 56.12%	3,490,628 $39 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $6.06 Million - $7.82 Million	-402,694 Reduced 15.26%	2,235,805 $34.5 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $7.69 Million - $12 Million	543,456 Added 25.94%	2,638,499 $50 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $2.04 Million - $3.3 Million	194,511 Added 10.23%	2,095,043 $31.9 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $10.5 Million - $24.2 Million	1,900,532 New	1,900,532 $24.2 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.